A detailed history of Israel Englander (Millennium Management LLC) transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Millennium Management LLC holds 681,874 shares of SNDX stock, worth $13.1 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
681,874
Previous 942,642 27.66%
Holding current value
$13.1 Million
Previous $20.4 Million 20.33%
% of portfolio
0.01%
Previous 0.01%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$19.71 - $24.57 $5.14 Million - $6.41 Million
-260,768 Reduced 27.66%
681,874 $16.2 Million
Q4 2023

Feb 14, 2024

BUY
$11.39 - $21.67 $9.01 Million - $17.1 Million
790,942 Added 521.39%
942,642 $20.4 Million
Q2 2023

Aug 14, 2023

BUY
$19.35 - $22.31 $2.13 Million - $2.45 Million
109,972 Added 263.54%
151,700 $3.18 Million
Q1 2023

May 15, 2023

BUY
$20.66 - $28.98 $862,100 - $1.21 Million
41,728 New
41,728 $881,000
Q2 2022

Aug 15, 2022

SELL
$13.64 - $19.48 $5.48 Million - $7.82 Million
-401,512 Reduced 94.23%
24,601 $473,000
Q1 2022

May 16, 2022

BUY
$14.84 - $22.15 $6.05 Million - $9.02 Million
407,351 Added 2171.15%
426,113 $7.41 Million
Q4 2021

Feb 14, 2022

SELL
$15.23 - $22.47 $275,495 - $406,459
-18,089 Reduced 49.09%
18,762 $411,000
Q3 2021

Nov 15, 2021

SELL
$13.87 - $19.8 $2.32 Million - $3.31 Million
-166,994 Reduced 81.92%
36,851 $704,000
Q2 2021

Aug 16, 2021

BUY
$13.42 - $25.18 $2.74 Million - $5.13 Million
203,845 New
203,845 $3.5 Million
Q1 2021

May 17, 2021

SELL
$19.28 - $24.59 $14.6 Million - $18.6 Million
-757,147 Closed
0 $0
Q4 2020

Feb 16, 2021

SELL
$15.1 - $26.44 $787,359 - $1.38 Million
-52,143 Reduced 6.44%
757,147 $16.8 Million
Q3 2020

Nov 16, 2020

SELL
$13.39 - $17.48 $706,429 - $922,209
-52,758 Reduced 6.12%
809,290 $11.9 Million
Q2 2020

Aug 14, 2020

BUY
$8.94 - $20.98 $5.19 Million - $12.2 Million
580,957 Added 206.68%
862,048 $12.8 Million
Q1 2020

May 14, 2020

BUY
$6.65 - $12.03 $1.68 Million - $3.03 Million
252,070 Added 868.58%
281,091 $3.08 Million
Q4 2019

Feb 14, 2020

SELL
$5.43 - $9.22 $9,632 - $16,356
-1,774 Reduced 5.76%
29,021 $255,000
Q3 2019

Nov 14, 2019

SELL
$7.47 - $10.76 $76,806 - $110,634
-10,282 Reduced 25.03%
30,795 $230,000
Q2 2019

Aug 15, 2019

SELL
$4.9 - $9.31 $2.25 Million - $4.27 Million
-458,923 Reduced 91.78%
41,077 $382,000
Q2 2019

Aug 14, 2019

BUY
$4.9 - $9.31 $2.12 Million - $4.03 Million
432,845 Added 644.55%
500,000 $5.06 Million
Q1 2019

May 14, 2019

BUY
$4.26 - $6.86 $71,099 - $114,493
16,690 Added 33.07%
67,155 $353,000
Q4 2018

Feb 14, 2019

SELL
$3.6 - $8.42 $2.01 Million - $4.69 Million
-557,573 Reduced 91.7%
50,465 $225,000
Q3 2018

Nov 14, 2018

BUY
$6.33 - $8.08 $2.91 Million - $3.71 Million
459,103 Added 308.26%
608,038 $4.91 Million
Q2 2018

Aug 14, 2018

SELL
$6.93 - $14.63 $1.33 Million - $2.81 Million
-192,378 Reduced 56.36%
148,935 $1.05 Million
Q1 2018

May 15, 2018

SELL
$8.71 - $14.82 $1.53 Million - $2.6 Million
-175,187 Reduced 33.92%
341,313 $4.86 Million
Q4 2017

Feb 14, 2018

BUY
$7.8 - $12.94 $641,596 - $1.06 Million
82,256 Added 18.94%
516,500 $4.53 Million
Q3 2017

Nov 14, 2017

BUY
$10.9 - $12.73 $4.73 Million - $5.53 Million
434,244
434,244 $5.08 Million

Others Institutions Holding SNDX

About Syndax Pharmaceuticals Inc


  • Ticker SNDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,565,200
  • Market Cap $1.09B
  • Description
  • Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...
More about SNDX
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.